Cardea’s COVID biosensor; plus gut microbes in Alzheimer’s risk and more

A group led by Cardea Bio Inc. co-founders Brett Goldsmith and Kiana Aran reported in Advanced Materials Technologies a graphene-based biosensor that detects antigen and RNA of SARS-CoV-2, including the Omicron variant, without the need for amplification. “The reported platform can be quickly adapted for multi-omics and multiplexed diagnosis of continuously evolving biothreats and global pandemics,” said the authors. 

Paragraf Ltd., a mass producer of graphene electronics, acquired Cardea in May...